Get App Open
In App
Open App
you are here:

Gland Pharma Ltd.

BSE: 543245 | NSE: GLAND |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE068V01023 | SECTOR: Pharmaceuticals & Drugs

BSE Live

Jun 02, 16:01
922.70 -9.45 (-1.01%)
Volume
AVERAGE VOLUME
5-Day
22,287
10-Day
102,553
30-Day
50,798
5,562
  • Prev. Close

    932.15

  • Open Price

    932.05

  • Bid Price (Qty.)

    922.70 (193)

  • Offer Price (Qty.)

    922.70 (7)

NSE Live

Jun 02, 15:59
922.25 -10.20 (-1.09%)
Volume
AVERAGE VOLUME
5-Day
388,741
10-Day
2,124,496
30-Day
1,109,668
332,720
  • Prev. Close

    932.45

  • Open Price

    936.00

  • Bid Price (Qty.)

    922.25 (8)

  • Offer Price (Qty.)

    0.00 (0)

Financials

2022 2021 2020 2019 2018
Profit & Loss account of Gland Pharma (in Rs. Cr.) Mar 23 Mar 22 Mar 21 Mar 20 Mar 19  
  12 mths 12 mths 12 mths 12 mths 12 mths  
INCOME  
Revenue From Operations [Gross] 3,616.53 4,384.15 3,423.64 2,571.78 1,993.15  
Less: Excise/Sevice Tax/Other Levies 0.00 0.00 0.00 0.00 0.00  
Revenue From Operations [Net] 3,616.53 4,384.15 3,423.64 2,571.78 1,993.15  
Total Operating Revenues 3,616.53 4,400.71 3,462.88 2,633.24 2,044.20  
Other Income 240.46 223.94 134.78 139.17 85.56  
Total Revenue 3,856.99 4,624.65 3,597.65 2,772.41 2,129.77  
EXPENSES  
Cost Of Materials Consumed 1,716.75 2,046.86 1,749.16 1,090.25 954.89  
Purchase Of Stock-In Trade 15.59 25.67 16.20 18.67 16.28  
Operating And Direct Expenses 0.00 95.05 74.59 78.50 74.03  
Changes In Inventories Of FG,WIP And Stock-In Trade -46.92 36.69 -273.49 -6.90 -114.15  
Employee Benefit Expenses 399.70 338.57 311.36 277.66 222.95  
Finance Costs 7.41 5.24 3.41 7.18 3.56  
Depreciation And Amortisation Expenses 146.74 110.30 98.78 94.59 81.96  
Other Expenses 512.85 347.23 282.79 219.59 183.89  
Total Expenses 2,752.13 3,005.61 2,262.80 1,779.54 1,423.41  
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax 1,104.86 1,619.04 1,334.85 992.87 706.36  
Exceptional Items -56.46 0.00 0.00 0.00 -20.00  
Profit/Loss Before Tax 1,048.40 1,619.04 1,334.85 992.87 686.36  
Tax Expenses-Continued Operations  
Current Tax 272.58 395.88 339.45 251.40 221.23  
Less: MAT Credit Entitlement 0.00 0.00 0.00 0.00 0.00  
Deferred Tax 0.00 14.01 0.12 -31.82 12.00  
Tax For Earlier Years 0.00 -3.00 -1.72 0.43 1.23  
Total Tax Expenses 272.58 406.89 337.85 220.01 234.45  
Profit/Loss After Tax And Before ExtraOrdinary Items 775.83 1,212.16 997.01 772.86 451.91  
Profit/Loss From Continuing Operations 775.83 1,212.16 997.01 772.86 451.91  
Profit/Loss For The Period 775.83 1,212.16 997.01 772.86 451.91  
OTHER ADDITIONAL INFORMATION  
EARNINGS PER SHARE  
Basic EPS (Rs.) 47.12 73.84 63.07 49.88 29.16  
Diluted EPS (Rs.) 47.11 73.67 62.99 49.88 29.16  
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS  
Imported Raw Materials 0.00 0.00 0.00 0.00 0.00  
Indigenous Raw Materials 0.00 0.00 0.00 0.00 0.00  
STORES, SPARES AND LOOSE TOOLS  
Imported Stores And Spares 0.00 0.00 0.00 0.00 0.00  
Indigenous Stores And Spares 0.00 0.00 0.00 0.00 0.00  
DIVIDEND AND DIVIDEND PERCENTAGE  
Equity Share Dividend 0.00 0.00 0.00 0.00 0.00  
Tax On Dividend 0.00 0.00 0.00 0.00 0.00  
Equity Dividend Rate (%) 0.00 0.00 0.00 0.00 0.00  
Source : Dion Global Solutions Limited

Results of Pharmaceuticals & Drugs Sector

No News.
No News.
No News.
No News.